Crucell signs PER.C6 licenses with ZyStor Therapeutics, Ferring Pharmaceuticals

By Ted A. Knutson

Washington, Dec. 21 - Crucell NV and allied contract manufacturer DSM Biologics announced Wednesday that they have signed a PER.C6 research license agreement with the private U.S. company ZyStor Therapeutics Inc. This agreement allows ZyStor to evaluate the PER.C6 cell line for use in the manufacturing of a specific therapeutic protein.

Crucell and DSM Biologics also announced that they have signed a second PER.C6 commercial license agreement with Ferring Pharmaceuticals. This license agreement allows Ferring to use the PER.C6 cell line in the production of a specific therapeutic protein.

As with the first license, the protein will be applied in the field of women's health care.

Financial details for both deals were not disclosed.

Crucell is a biotechnology company based in Leiden, The Netherlands, that develops vaccines and antibodies.

The announcement was made in an 8-K filing with the Securities and Exchange Commission.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.